Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:Might be

[CancerSlayer]

CancerSlayer wrote:

thadeush wrote: The only thing Kennedy and Oz, like every one of tRump's appointments, will definitely be looking for are ways for them to make money and undermine the FDA so that all the money flows to them and their billionaire donors. Luck is what we need when those sh*t stains get in there and the FDA becomes a circus. Their public disdain for actual cures and support for 'natural' cures might work in TLT's favour - but only if they see a way to make the doe-ray-me. 

Unfortunately, the powerful clout/influence of the FDA crosses party lines. Between the 2016 & 2022 election cycles, the top 10 Pharmas gave $53 million to both parties, of which the Democrats received $29 million.

Ultimately, a successful FDA will be a more efficient & adequately funded FDA.  The upcoming deregulatory environment in the US may be challenging, but could actually expedite the approval process (for good or bad) & increase the FDA's appetite for less traditional treatments, especially treatments "not" coming from your usual BP suspects.  

For all we know, RDW may be strategizing/incentivized to keep as much ownership of this company for as long as possible (i.e. with the goal of preserving our IP & out-licensing our treatment vs potentially being devoured by an M&A or other less friendly partnership)....thereby forgoing immediate $ gratification for bigger & more long-term financial success.  This = better news for our younger shareholders (< 70 ; ) & makes getting that BTD even more paramount.  JMO...

Highlighted Correction:  meant Big Pharma...not FDA

Unfortunately, the powerful clout/influence of Big Pharma crosses party lines. Between the 2016 & 2022 election cycles, the top 10 Pharmas gave $53 million to both parties, of which the Democrats received $29 million.

Ultimately, a successful FDA will be a more efficient & adequately funded FDA.  The upcoming deregulatory environment in the US may be challenging, but could actually expedite the approval process (for good or bad) & increase the FDA's appetite for less traditional treatments, especially treatments "not" coming from your usual BP suspects.  

For all we know, RDW may be strategizing/incentivized to keep as much ownership of this company for as long as possible (i.e. with the goal of preserving our IP & out-licensing our treatment vs potentially being devoured by an M&A or other less friendly partnership)....thereby forgoing immediate $ gratification for bigger & more long-term financial success.  This = better news for our younger shareholders (< 70 ; ) & makes getting that BTD even more paramount.  JMO...